Osarenren Ogbeide, MD
Hematology & Oncology · Memphis, TNNPI 1952375156
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Gilead at 54.7% of the total. Reporting peaked in 2023 at $8,396 and has fallen 85.4% since, to $1,229 in 2025.
Across 145 payments — averaging $92.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- AstraZeneca$2K
- Sanofi$850
- Intuitive Surgical$464
- Exelixis Inc.$377
- E.r. Squibb & Sons, L.L.C.$296
- plus $2K from 27 others
Across 15 payments — averaging $3918.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$24K
- Biontech SE$20K
- Genentech, Inc.$15K
What the payments were for
- Consulting fees$7,74557%
- Speaking & faculty fees$8506%
- Travel & lodging$1,1248%
- Food & beverage$3,59027%
- Education$1691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 17 | $7,371 |
| AstraZeneca | 8 | $2,008 |
| Sanofi | 3 | $850 |
| Intuitive Surgical | 3 | $464 |
| Exelixis Inc. | 5 | $377 |
| E.r. Squibb & Sons, L.L.C. | 18 | $296 |
| Merck | 14 | $295 |
| AbbVie | 10 | $229 |
| GSK | 10 | $209 |
| Bristol Myers Squibb | 9 | $188 |
| Novartis | 7 | $145 |
| Pfizer | 8 | $140 |
| Iovance Biotherapeutics, Inc. | 1 | $137 |
| Eli Lilly | 1 | $105 |
| Tempus AI, Inc | 4 | $86 |
| Eisai Inc. | 4 | $83 |
| Daiichi Sankyo Inc. | 3 | $72 |
| ADC Therapeutics America, Inc. | 1 | $65 |
| Amgen | 3 | $53 |
| Bayer | 2 | $35 |
| Johnson & Johnson | 2 | $35 |
| Springworks Therapeutics, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Beigene USA, Inc. | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Incyte Corporation | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,479 in reported general payments places this provider in the 65th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NinlaroIxazomib Citrate | 26 | $329,536 |
| Lenalidomide | 22 | $316,771 |
| TagrissoOsimertinib Mesylate | 15 | $243,133 |
| Abiraterone Acetate | 18 | $143,257 |
| XareltoRivaroxaban | 40 | $37,142 |
| EliquisApixaban | 39 | $22,040 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,582 |
| Potassium Chloride | 55 | $659 |
| Ondansetron OdtOndansetron | 43 | $627 |
| Megestrol Acetate | 12 | $626 |
| Dexamethasone | 57 | $522 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $511 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $461 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $394 |
| Oxycodone Hcl | 19 | $381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,008 | $243,13315 claims |
| Johnson & JohnsonXarelto | $35 | $37,14240 claims |
| PfizerEliquis | $140 | $22,04039 claims |
| GSKTrelegy Ellipta | $209 | $7,58212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Memphis
- Ugochi OguMemphis$250K
- Patricia Adams-GravesMemphis$168K
- Donald GravenorMemphis$166K
- Aleksandar JankovMemphis$163K
- Brion RandolphMemphis$162K
- Kenneth AtagaMemphis$157K
- Raymond OsarogiagbonMemphis$117K
- Saurin ChokshiMemphis$86K
- Clyde JonesMemphis$54K
- Salil GoorhaMemphis$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.